Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study
Frontiers in Pediatrics · 15.06.2026 · 14
DOI: 10.3389/fped.2026.1808733 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Pediatrics, online erschienen am 15.06.2026. Verfasst von Ahlam Mazi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Asthma is common in children. Dupilumab is a biological agent that showed effectiveness in older children with uncontrolled asthma; however, its efficacy and safety are lacking among the very young children (≤6) who were excluded from clinical trials.
Methods
Using TriNetX, children ≤6 years old with persistent asthma who received a concomitant prescription for dupilumab for any indication, in addition to standard asthma treatment, were compared with those on standard treatment alone. Using 1:1 propensity score matching across 35 covariates, outcomes such as acute exacerbations, status asthmaticus, need for oral corticosteroid (OCS), emergency room (ER) visits, anaphylaxis, infections, and inpatient admissions were assessed at 6 and 12 months.
Results
Of 44,952 patients analyzed, 301 patients were matched per group. Asthmatic children with concomitant dupilumab prescriptions were associated with a reduction in acute exacerbations at 6 and 12 months (RR 0.53 and 0.46, respectively; p < 0.05), OCS use (RR 0.67 and 0.66; p < 0.05), ER visits, and infections (all p < 0.05). However, the risk of anaphylaxis was higher in cohort one at 6 and 12 months (RR 1.80 and 1.74; p < 0.05). Other outcomes, such as status asthmaticus, eosinophilia, and inpatient admissions, were similar between the cohorts.
Conclusions
This real-world analysis shows dupilumab therapy alongside standard treatment in children ≤6 years with persistent asthma is significantly associated with reduced acute exacerbations, OCS use, and ER visits. These findings support dupilumab's clinical benefit for this vulnerable group, aiding clinical decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Pediatrics, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah, Saudi Arabia.
- Child and Women Health Department, Faculty of Medicine, Taibah University, Medina, Saudi Arabia.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
- Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Zitieren
APA
Mazi, A., Aljohany, A., Fouad, M., Hamadallah, H., Bukhari, E. M., Bayomi, D., Alsulaimani, S., Gazzaz, N., Sharara, M., & Dobs, M. (2026). Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1808733
Vancouver
Mazi A, Aljohany A, Fouad M, Hamadallah H, Bukhari EM, Bayomi D, et al. Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1808733
BibTeX
@article{Mazi2026,
author = {Mazi, Ahlam and Aljohany, Azizah and Fouad, Michele and Hamadallah, Hanaa and Bukhari, Esraa M and Bayomi, Doaa and Alsulaimani, Samahir and Gazzaz, Nour and Sharara, Muhannad and Dobs, Monica},
title = {Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {14},
doi = {10.3389/fped.2026.1808733}
}
EUVIMED